BKV three-lens brief
Evidence-based stock research on BKV. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 12% of its 52-week range — deep in the lower band.
- Trading at 12% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 9.5pp over 30 days.
- P/E of 8.9 — trading at a value multiple.
- Analyst mean target $32.27 — 68% above current (11 analysts).
BKV closed at $19.24 (+1.48%) as of 2026-11-12. Market cap: $2.08B. P/E (trailing) 8.9. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 8.9 — trading at a value multiple.; analyst mean target $32.27 — 68% above current (11 analysts).. Concerns: trading at 12% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $478.37M, net income $29.43M, free cash flow -$547.03M.
Why three lenses on BKV, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BKV across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BKV" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BKV brief"></iframe>